Takeda overhauls management under Weber's leadership
This article was originally published in Scrip
Executive Summary
New senior management changes at Takeda bear the globalizing hallmark of Christophe Weber, who became chief operating officer in April and president in June, and who is expected to take the helm as CEO in the not too distant future. On 16 September Takeda announced a major organizational overhaul, establishing five regional business units, separating the Japan pharma business from the North Asian unit, and merging North Asian into Emerging Market. The goal is "to establish an operation system meeting patients' and medical professionals' needs."
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.